原始出處紀錄
決策級主要結果 (Topline)
Veradermics 公布 VDPHL01 治療男性型禿髮的 2/3 期頂線數據正面結果
302 號 2/3 期試驗達成所有主要及關鍵次要終點，且具統計學意義。VDPHL01 在第 6 個月時相較安慰劑，產生快速且具劑量依賴性的非毳毛毛髮數量增加，以及患者自評毛髮覆蓋率提升，安全性概況普遍耐受良好，無治療相關嚴重不良事件或心臟相關不良事件特別關注。
關鍵事實
來源摘錄
mane-20260427 0001827635 False 0001827635 2026-04-27 2026-04-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2026 VERADERMICS, INCORPORATED (Exact name of registrant as specified in its charter) Delaware 001-43097 84-3304423 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 470 James Street New Haven , CT 06513 (Address of principal executive offices) (Zip Code) (Registrant’s telephone number, including area code): ( 228 ) 372-3376 Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Fo